SYS-CON MEDIA Authors: Xenia von Wedel, Peter Silva, Glenn Rossman, Ava Smith, Elizabeth White

News Feed Item

Trichotillomania Global Clinical Trials Review, H2, 2014

LONDON, Aug. 25, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:

Trichotillomania Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2312348/Trichotillomania-Global-Clinical-Trials-Review-H2-2014.html

Trichotillomania Global Clinical Trials Review, H2, 2014

Summary

GlobalData's clinical trial report, "Trichotillomania Global Clinical Trials Review, H2, 2014" provides data on the Trichotillomania clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Trichotillomania. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Trichotillomania. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
- Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

- Understand the dynamics of a particular indication in a condensed manner
- Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
- Obtain discontinued trial listing for trials across the globe
- Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Trichotillomania 5
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Countries Contributing to Clinical Trials in North America 8
Top Countries Contributing to Clinical Trials in Middle East and Africa 9
Top Countries Contributing to Clinical Trials in Central and South America 10
Clinical Trials by G7 Countries: Proportion of Trichotillomania to Central Nervous System Clinical Trials 11
Clinical Trials by Phase in G7 Countries 12
Clinical Trials in G7 Countries by Trial Status 13
Clinical Trials by E7 Countries: Proportion of Trichotillomania to Central Nervous System Clinical Trials 14
Clinical Trials by Phase 15
In Progress Trials by Phase 16
Clinical Trials by Trial Status 17
Clinical Trials by End Point Status 18
Subjects Recruited Over a Period of Time 19
Clinical Trials by Sponsor Type 20
Prominent Drugs 21
Clinical Trial Overview of Top Institutes / Government 22
National Institute of Mental Health 22
Clinical Trial Overview of National Institute of Mental Health 22
Massachusetts General Hospital 23
Clinical Trial Overview of Massachusetts General Hospital 23
University of Chicago 24
Clinical Trial Overview of University of Chicago 24
American University of Beirut Medical Center 25
Clinical Trial Overview of American University of Beirut Medical Center 25
Yale University 26
Clinical Trial Overview of Yale University 26
University of South Florida 27
Clinical Trial Overview of University of South Florida 27
University of Sao Paulo 28
Clinical Trial Overview of University of Sao Paulo 28
Hamilton Health Sciences 29
Clinical Trial Overview of Hamilton Health Sciences 29
University of Pennsylvania 30
Clinical Trial Overview of University of Pennsylvania 30
Stanford University 31
Clinical Trial Overview of Stanford University 31
Five Key Clinical Profiles 32
Appendix 49
Abbreviations 49
Definitions 49
Research Methodology 50
Secondary Research 50
About GlobalData 51
Contact Us 51
Disclaimer 51
Source 51

List of Tables
Trichotillomania Therapeutics, Global, Clinical Trials by Region, 2014* 6
Trichotillomania Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Trichotillomania Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014* 7
Trichotillomania Therapeutics Clinical Trials, North America, Top Countries, 2014* 8
Trichotillomania Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014* 9
Trichotillomania Therapeutics Clinical Trials, Central and South America, Top Countries, 2014* 10
Proportion of Trichotillomania to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 11
Trichotillomania Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 12
Trichotillomania Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 13
Proportion of Trichotillomania to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 14
Trichotillomania Therapeutics, Global, Clinical Trials by Phase, 2014* 15
Trichotillomania Therapeutics, Global, Clinical Trials In Progress by Phase 2014* 16
Trichotillomania Therapeutics, Global, Clinical Trials by Trial Status, 2014* 17
Trichotillomania Therapeutics Clinical Trials, Global, by End Point Status, 2014* 18
Trichotillomania Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 19
Trichotillomania Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014* 20
Trichotillomania Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014* 21
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by National Institute of Mental Health, 2014* 22
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2014* 23
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Chicago, 2014* 24
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by American University of Beirut Medical Center, 2014* 25
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by Yale University, 2014* 26
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by University of South Florida, 2014* 27
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Sao Paulo, 2014* 28
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by Hamilton Health Sciences, 2014* 29
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Pennsylvania, 2014* 30
Trichotillomania Therapeutics Clinical Trials Market, Global, Clinical Trials by Stanford University, 2014* 31

List of Figures
Trichotillomania Therapeutics, Global, Clinical Trials by Region (%), 2014* 6
Trichotillomania Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014* 7
Trichotillomania Therapeutics Clinical Trials, North America, Top Countries (%), 2014* 8
Proportion of Trichotillomania to Central Nervous System Clinical Trials, G7 Countries (%), 2014* 11
Trichotillomania Therapeutics, G7 Countries, Clinical Trials by Phase, 2014* 12
Trichotillomania Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014* 13
Proportion of Trichotillomania to Central Nervous System Clinical Trials, E7 Countries (%), 2014* 14
Trichotillomania Therapeutics, Global, Clinical Trials by Phase (%), 2014* 15
Trichotillomania Therapeutics, Global, Clinical Trials In Progress by Phase, 2014* 16
Trichotillomania Therapeutics, Global, Clinical Trials by Trial Status, 2014* 17
Trichotillomania Therapeutics Clinical Trials, Global, by End Point Status, 2014* 18
Trichotillomania Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013 19
Trichotillomania Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014* 20
GlobalData Methodology 50


Read the full report:
Trichotillomania Global Clinical Trials Review, H2, 2014

https://www.reportbuyer.com/product/2312348/Trichotillomania-Global-Clinical-Trials-Review-H2-2014.html

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

SOURCE ReportBuyer

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
The definition of IoT is not new, in fact it’s been around for over a decade. What has changed is the public's awareness that the technology we use on a daily basis has caught up on the vision of an always on, always connected world. If you look into the details of what comprises the IoT, you’ll see that it includes everything from cloud computing, Big Data analytics, “Things,” Web communication, applications, network, storage, etc. It is essentially including everything connected online from ha...
We are all here because we are sold on the transformative promise of The Cloud. But what good is all of this ephemeral, on-demand infrastructure if your usage doesn't actually improve the agility and speed of your business? How must Operations adapt in order to avoid stifling your Cloud initiative? In his session at DevOps Summit, Damon Edwards, co-founder and managing partner of the DTO Solutions, will highlight the successful organizational, process, and tooling patterns of high-performing c...
Software-driven innovation is becoming a primary approach to how businesses create and deliver new value to customers. A survey of 400 business and IT executives by the IBM Institute for Business Value showed businesses that are more effective at software delivery are also more profitable than their peers nearly 70 percent of the time (1). DevOps provides a way for businesses to remain competitive, applying lean and agile principles to software development to speed the delivery of software that ...
Docker offers a new, lightweight approach to application portability. Applications are shipped using a common container format and managed with a high-level API. Their processes run within isolated namespaces that abstract the operating environment independently of the distribution, versions, network setup, and other details of this environment. This "containerization" has often been nicknamed "the new virtualization." But containers are more than lightweight virtual machines. Beyond their small...
The move in recent years to cloud computing services and architectures has added significant pace to the application development and deployment environment. When enterprise IT can spin up large computing instances in just minutes, developers can also design and deploy in small time frames that were unimaginable a few years ago. The consequent move toward lean, agile, and fast development leads to the need for the development and operations sides to work very closely together. Thus, DevOps become...
Cloud Expo 2014 TV commercials will feature @ThingsExpo, which was launched in June, 2014 at New York City's Javits Center as the largest 'Internet of Things' event in the world.

ARMONK, N.Y., Nov. 20, 2014 /PRNewswire/ --  IBM (NYSE: IBM) today announced that it is bringing a greater level of control, security and flexibility to cloud-based application development and delivery with a single-tenant version of Bluemix, IBM's

An entirely new security model is needed for the Internet of Things, or is it? Can we save some old and tested controls for this new and different environment? In his session at @ThingsExpo, New York's at the Javits Center, Davi Ottenheimer, EMC Senior Director of Trust, reviewed hands-on lessons with IoT devices and reveal a new risk balance you might not expect. Davi Ottenheimer, EMC Senior Director of Trust, has more than nineteen years' experience managing global security operations and asse...
The major cloud platforms defy a simple, side-by-side analysis. Each of the major IaaS public-cloud platforms offers their own unique strengths and functionality. Options for on-site private cloud are diverse as well, and must be designed and deployed while taking existing legacy architecture and infrastructure into account. Then the reality is that most enterprises are embarking on a hybrid cloud strategy and programs. In this Power Panel at 15th Cloud Expo (http://www.CloudComputingExpo.com...
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at Internet of @ThingsExpo, James Kirkland, Chief Ar...
Leysin American School is an exclusive, private boarding school located in Leysin, Switzerland. Leysin selected an OpenStack-powered, private cloud as a service to manage multiple applications and provide development environments for students across the institution. Seeking to meet rigid data sovereignty and data integrity requirements while offering flexible, on-demand cloud resources to users, Leysin identified OpenStack as the clear choice to round out the school's cloud strategy. Additional...
Technology is enabling a new approach to collecting and using data. This approach, commonly referred to as the "Internet of Things" (IoT), enables businesses to use real-time data from all sorts of things including machines, devices and sensors to make better decisions, improve customer service, and lower the risk in the creation of new revenue opportunities. In his General Session at Internet of @ThingsExpo, Dave Wagstaff, Vice President and Chief Architect at BSQUARE Corporation, discuss the ...
The security devil is always in the details of the attack: the ones you've endured, the ones you prepare yourself to fend off, and the ones that, you fear, will catch you completely unaware and defenseless. The Internet of Things (IoT) is nothing if not an endless proliferation of details. It's the vision of a world in which continuous Internet connectivity and addressability is embedded into a growing range of human artifacts, into the natural world, and even into our smartphones, appliances, a...
SYS-CON Media announced today that Aruna Ravichandran, VP of Marketing, Application Performance Management and DevOps at CA Technologies, has joined DevOps Journal’s authors. DevOps Journal is focused on this critical enterprise IT topic in the world of cloud computing. DevOps Journal brings valuable information to DevOps professionals who are transforming the way enterprise IT is done. Aruna's inaugural article "Four Essential Cultural Hacks for DevOps Newbies" discusses how to demonstrate the...
"BSQUARE is in the business of selling software solutions for smart connected devices. It's obvious that IoT has moved from being a technology to being a fundamental part of business, and in the last 18 months people have said let's figure out how to do it and let's put some focus on it, " explained Dave Wagstaff, VP & Chief Architect, at BSQUARE Corporation, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4-6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.